RADIANT Trial Results: The Impact on Type 1 Diabetes (T1D) Patients and a Glimpse into the Future of Diabetes Care

What happens when you transition type 1 diabetes (T1D) patients from multiple daily injections (MDI) to Omnipod 5 using Abbott’s Freestyle Libre 2?  That is exactly what the RADIANT Randomized Controlled Trial (RCT) investigated.    Listen to Within Range with Kate Neal, Clinical Services Manager at Insulet who is joined by Dr. Emma Wilmot - Associate Professor at University of Nottingham, consultant Diabetologist, & founder of the Diabetes Technology Network UK - to unpack the incredible results of the RADIANT trial and discuss its impact on patients and the future of diabetes care.  Recently published in The Lancet Diabetes & Endocrinology journal, Dr Emma Wilmot shares not just the results of the RADIANT trial but also how she approaches onboarding her patients with Automated Insulin Delivery (AID), highlighting the importance of peer support, and how she is contributing to reducing the daily burden of those living with type 1 diabetes (t1d).  ---  How can continuous glucose monitoring and tubeless insulin delivery help people living with diabetes? Within Range is a podcast for healthcare professionals (HCPs), helping them stay up to date on the latest diabetes innovations.  Within Range is presented by Kate Neal and Cindy Pickering (Clinical Services Managers at Insulet) who sit down with diabetes healthcare professionals from across the world to discuss clinical research, best practices and how Omnipod 5 Automated Insulin Delivery systems (AIDs) can help simplify diabetes management for patients with Type 1 diabetes (T1D).  If you’re looking to improve your patient’s time in range as well as time in happiness, then this is the podcast for you.  ---  Disclaimer  Note: The information in this podcast is accurate to the date of recording as of 12/03/2024. Dr. Emma Wilmot’s, views and opinions expressed in this podcast are her own and do not necessarily reflect those of Insulet.  This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety.  For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.  © Insulet Corporation. All rights reserved. INS-OHS-04-2026-00067 v1.0